Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma

The goal of this clinical trial is to learn if adding high-dose-rate (HDR) brachytherapy can improve outcomes in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who have already received external beam radiotherapy (EBRT), chemotherapy, and the immune therapy drug nivolumab. The main questions it aims to answer are: * Does HDR brachytherapy reduce the chance of the cancer coming back in the esophagus or nearby areas within 12 months? * What side effects or safety issues occur when HDR brachytherapy is given after EBRT, chemotherapy, and nivolumab? Participants will:

Trial Details

NCT ID
NCT07152678
Phase
PHASE2
Sponsor
National Taiwan University Hospital
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Nivolumab (240 mg)
  • Brachytherapy
Locations (sample)
  • Huwei, Yunlin County, Taiwan|23.71212,120.4335

Key Eligibility Criteria

  • Age of 18-85 years, with ECOG performance 0-2.
  • Locally-advanced esophageal squamous cell carcinoma with clinical stage III, IVA with biopsy proven.
  • Prior treatment with EBRT (40-50.4 Gy in 20-28 fractions) and platinum + fluoropyrimidine chemotherapy, with residual or progressive disease, and d…
  • No prior exposure to ICIs and had received first cycle of nivolumab after CCRT.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →